trial

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)

NCTId NCT00174265
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 196 (actual)
Sponsored by Organon and Co
Primary completion 2009-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
196 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
Quadruple
Start
2005-07
Primary completion
2009-04
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AsenapineOlanzapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Linked catalysts

1
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patien — primary completion2009-04

Facts & assertions

4 sourced
Enrollment
196
Phase
PHASE3
Primary Completion Date
2009-04
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
Olanzapine
drug
lead_sponsor
Organon and Co
company
indication
Schizophrenia
indication
Schizophrenia
indication